secwatch.observer — SEC 8-K summary
======================================

Issuer:     AbbVie Inc. (ABBV)
CIK:        0001551152
Form:       8-K
Filed at:   2026-04-29T23:59:59+00:00
Accession:  0001551152-26-000013
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AbbVie Q1 adjusted EPS $2.65 (+7.7%), revenue $15.0B (+12.4%); raises FY2026 guidance
--------------------------------------------------------------------------------

- GAAP diluted EPS $0.39, down 45.8%; adjusted EPS $2.65, up 7.7%, with $0.41 IPR&D headwind.
- Net revenue $15.002B, +12.4% reported / +10.3% operational; immunology portfolio $7.290B (+16.4%).
- Skyrizi $4.483B (+30.9%), Rinvoq $2.119B (+23.3%), Humira $688M (-38.6%); neuroscience +26%.
- FY2026 adjusted EPS guidance raised to $14.08-$14.28 from $13.96-$14.16.
- FDA CRL for trenibotulinumtoxinE on manufacturing; no safety/efficacy issues; expects prompt refiling.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1551152/000155115226000013/0001551152-26-000013-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1551152/000155115226000013/abbv-20260429.htm
  HTML page:      https://secwatch.observer/filing/0001551152-26-000013

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer